Silver Book Fact

Use of shingles vaccines significantly reduced disease burden

Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.

Oxman, M.N., M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, et al; for the Shingles Prevention Study Group. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. NEJM. 2005; 352(22): 2271-84. http://www.nejm.org/doi/full/10.1056/NEJMoa051016

Reference

Title
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
NEJM
Publication Date
2005
Authors
Oxman, M.N., M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, et al; for the Shingles Prevention Study Group
Volume & Issue
Volume 352, Issue 22
Pages
2271-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Economic value from flu vaccine in elderly
    As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest…  
  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.